Literature DB >> 26926438

Proteomic MALDI-TOF/TOF-IMS examination of peptide expression in the formalin fixed brainstem and changes in sudden infant death syndrome infants.

Nicholas J Hunt1, Leo Phillips2, Karen A Waters3, Rita Machaalani4.   

Abstract

Matrix assisted laser desorption/ionisation imaging mass spectrometry (MALDI-IMS) has not previously been utilised to examine sudden infant death syndrome (SIDS). This study aimed to optimise MALDI IMS for use on archived formalin-fixed-paraffin-embedded human infant medulla tissue (n=6, controls; n=6, SIDS) to evaluate differences between multiple nuclei of the medulla by using high resolution IMS. Profiles were compared between SIDS and age/sex matched controls. LC-MALDI identified 55 proteins based on 321 peptides across all samples; 286 peaks were found using IMS, corresponding to these 55 proteins that were directly compared between controls and SIDS. Control samples were used to identify common peptides for neuronal/non-neuronal structures allowing identification of medullary regions. In SIDS, abnormal expression patterns of 41 peptides (p≤0.05) corresponding to 9 proteins were observed; these changes were confirmed with immunohistochemistry. The protein abnormalities varied amongst nuclei, with the majority of variations in the raphe nuclei, hypoglossal and pyramids. The abnormal proteins are not related to a previously identified neurological disease pathway but consist of developmental neuronal/glial/axonal growth, cell metabolism, cyto-architecture and apoptosis components. This suggests that SIDS infants have abnormal neurological development in the raphe nuclei, hypoglossal and pyramids of the brainstem, which may contribute to the pathogenesis of SIDS. BIOLOGICAL SIGNIFICANCE: This study is the first to perform an imaging mass spectrometry investigation in the human brainstem and also within sudden infant death syndrome (SIDS). LC MALDI and MALDI IMS identified 55 proteins based on 285 peptides in both control and SIDS tissue; with abnormal expression patterns present for 41/285 and 9/55 proteins in SIDS using IMS. The abnormal proteins are critical for neurological development; with the impairment supporting the hypothesis that SIDS may be due to delayed neurological maturation. The brainstem regions mostly affected included the raphe nuclei, hypoglossal and pyramids. This study highlights that basic cyto-architectural proteins are affected in SIDS and that abnormal expression of these proteins in other CNS disorders should be examined. KEY SENTENCES: LC MALDI and MALDI IMS identified 55 proteins based on 285 peptides in both control and SIDS tissue. Abnormal expression patterns were present for 41/285 and 9/55 proteins in SIDS using IMS. Brainstem regions mostly affected included the raphe nuclei, hypoglossal and pyramids.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Brain; Human; Imaging mass spectrometry; Immunohistochemistry; Paraffin-embedded; SIDS

Mesh:

Substances:

Year:  2016        PMID: 26926438     DOI: 10.1016/j.jprot.2016.02.022

Source DB:  PubMed          Journal:  J Proteomics        ISSN: 1874-3919            Impact factor:   4.044


  3 in total

1.  Characterisation of medullary astrocytic populations in respiratory nuclei and alterations in sudden unexpected death in epilepsy.

Authors:  Smriti Patodia; Beatrice Paradiso; Matthew Ellis; Alyma Somani; Sanjay M Sisodiya; Orrin Devinsky; Maria Thom
Journal:  Epilepsy Res       Date:  2019-10-01       Impact factor: 3.045

2.  IGFBP-3 interacts with NONO and SFPQ in PARP-dependent DNA damage repair in triple-negative breast cancer.

Authors:  Hasanthi C de Silva; Mike Z Lin; Leo Phillips; Janet L Martin; Robert C Baxter
Journal:  Cell Mol Life Sci       Date:  2019-02-06       Impact factor: 9.261

Review 3.  Sudden Infant Death Syndrome: Beyond Risk Factors.

Authors:  Serafina Perrone; Chiara Lembo; Sabrina Moretti; Giovanni Prezioso; Giuseppe Buonocore; Giorgia Toscani; Francesca Marinelli; Francesco Nonnis-Marzano; Susanna Esposito
Journal:  Life (Basel)       Date:  2021-02-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.